

From the Editor's desk

By Kamaldeep Bhui

Time, tenacity and trials: improving the quality of research

Medical research studies are increasing in number but evaluating efficacy, effectiveness, and public health impact of new interventions remains difficult because of inconsistent reporting in scientific journals. The CONSORT guidelines for reporting randomised trials were recommended over 15 years ago,¹ and were adopted by many journals across disciplinary boundaries and specialties.^{2–5} The guidelines have clear implications for trial design and execution.⁶ Further guidelines have emerged for the reporting of systematic reviews and observational studies.⁷ These guidelines aim to improve transparency in research to inform decisions about clinical effectiveness and treatment recommendations. Have these guidelines had sufficient impact on the reporting and the accessibility of research to the wider public, as well as clinicians and researchers? It appears that the answer to this is no, at least not in psychiatry^{8,9} nor for pharmacological¹⁰ and non-pharmacological trials in general,¹¹ for trials of treatments for cancer¹² nor for some trials in anaesthetics.¹³ Psychiatric studies are especially challenging as the trials can include pharmacological and non-pharmacological interventions, devices, surgery, psychological treatments, complex multi-component interventions in hospital or community settings, public health and policy interventions in single or cluster randomised designs, and more. Are these multiple study designs a reason why the guidelines are not more widely used in mental health research? The CONSORT group have been busy generating evidence for effective ways of improving uptake of the guidelines, not least creating guidelines for parallel group designs,¹⁴ social and psychological interventions,¹⁵ addictions research,¹⁶ trials in child and adolescent mental health services,¹⁷ cluster randomised trials of those with cognitive impairment,¹⁸ and pragmatic trials in general.¹⁹

The number of trials in psychiatric and mental health research is increasing, as seen in the trends in the BJPsych; for example, Chien & Thompson (pp. 52–59) in this month's *Journal* show that mindfulness-based group psychoeducation for patients with schizophrenia leads to improvement in symptoms, function, insight and readmissions profile at 2-year follow-up. Other designs are still needed in psychiatric and mental health research; for example, in this issue there are studies that seek to identify biomarkers to improve diagnosis (see Howes & Kapur, pp. 1–3; Pearlman *et al.*, pp. 8–16; and Li *et al.*, pp. 29–35), and to understand aetiology and developmental pathways to mental disorders in order to identify new interventions (Stringaris *et al.*, pp. 17–23; Hung *et al.*, pp. 24–28; Gumley *et al.*, pp. 60–67; Muralidharan *et al.*, pp. 36–43). Two important issues are raised by observational studies that show a higher mortality risk associated with antipsychotic use in people with cognitive impairment (see Gerhard *et al.*, pp. 44–51 and the linked editorial by Ballard *et al.*, pp. 4–5) and in behavioural management in people with intellectual disabilities (see editorial by Glover *et al.*, pp. 6–7). Prescribing without any scientific rationale is still common, so better evidence is needed about mechanisms by which psychiatric illness emerges and can be prevented and treated.

The skills, tenacity, temperament and time required to progress research along the pathway towards new and effective interventions always seem more than patients, researchers, clinicians, commissioners and policy makers would like. As a refreshing counterpoint to this proliferation of best evidence, Patterson *et al* (pp. 68–75) argue that including service users in research can lead to realisation of benefits. Indeed, the way research is assessed for impact is rapidly evolving, and patient involvement in both the design and execution of clinical research may well be the way we can be assured of more meaningful progress²⁰ while ensuring that the evidence-based agenda remains relevant to everyday experiences of patients and clinicians.²¹

- 1 Schulz KF. The quest for unbiased research: randomized clinical trials and the CONSORT reporting guidelines. *Ann Neurol* 1997; **41**: 569–73.
- 2 Newcombe RG. Reporting of clinical trials in the JO – the CONSORT Guidelines. *J Orthod* 2000; **27**: 69–70.
- 3 Grimes DA. The "CONSORT" guidelines for randomized controlled trials in *Obstetrics & Gynecology*. *Obstet Gynecol* 2002; **100**: 631–2.
- 4 Calvert M, McManus R, MacLeod J. Timing of simvastatin treatment: trial is not reported according to CONSORT guidelines. *BMJ* 2004; **328**: 167–8.
- 5 Bennett JA. The Consolidated Standards of Reporting Trials (CONSORT): Guidelines for reporting randomized trials. *Nurs Res* 2005; **54**: 128–32.
- 6 Leitao Jr MM, Goldsmith LT. Optimal study design and the CONSORT guidelines. *Fertil Steril* 2005; **84**: 1057–8.
- 7 Brand RA. Standards of reporting: the CONSORT, QUORUM, and STROBE guidelines. *Clin Orthop Relat Res* 2009; **467**: 1393–4.
- 8 Han C, Kwak KP, Marks DM, Pae CU, Wu LT, Bhatia KS, et al. The impact of the CONSORT statement on reporting of randomized clinical trials in psychiatry. *Contemp Clinical Trials* 2009; **30**: 116–22.
- 9 Motraghi TE, Seim RW, Meyer EC, Morissette SB. Virtual reality exposure therapy for the treatment of posttraumatic stress disorder: a methodological review using CONSORT guidelines. *J Clin Psychol* 2014; **70**: 197–208.
- 10 Dasi F, Navarro-Garcia MM, Jimenez-Heredia M, Magraner J, Vina JR, Pallardo FV, et al. Evaluation of the quality of publications on randomized clinical trials using the Consolidated Standards of Reporting Trials (CONSORT) statement guidelines in a Spanish tertiary hospital. *J Clin Pharmacol* 2012; **52**: 1106–14.
- 11 Nagendran M, Harding D, Teo W, Camm C, Maruthappu M, McCulloch P, et al. Poor adherence of randomised trials in surgery to CONSORT guidelines for non-pharmacological treatments (NPT): a cross-sectional study. *BMJ Open* 2013; **3**: e003898.
- 12 Peron J, Maillet D, Gan HK, Chen EX, You B. Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review. *J Clin Oncol* 2013; **31**: 3957–63.
- 13 Farr BM. Unclear study methods still confusing readers despite CONSORT guidelines (e.g., lidocaine patch does relieve pain of covered rib fractures). *J Clin Epidemiol* 2014; **67**: 356–7.
- 14 Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *Int J Surg* 2012; **10**: 28–55.
- 15 Grant SP, Mayo-Wilson E, Melendez-Torres GJ, Montgomery P. Reporting quality of social and psychological intervention trials: a systematic review of reporting guidelines and trial publications. *Plos One* 2013; **8**: e65442.
- 16 Grant S, Mayo-Wilson E, Hopewell S, Macdonald G, Moher D, Montgomery P. New guidelines are needed to improve the reporting of trials in addiction sciences. *Addiction* 2013; **108**: 1687–8.
- 17 Gardner F, Mayo-Wilson E, Montgomery P, Hopewell S, Macdonald G, Moher D, et al. The need for new guidelines to improve the reporting of trials in child and adolescent mental health. *J Child Psychol Psychiatry* 2013; **54**: 810–2.
- 18 DiazOrdaz K, Slowther A-M, Potter R, Eldridge S. Consent processes in cluster-randomised trials in residential facilities for older adults: a systematic review of reporting practices and proposed guidelines. *BMJ Open* 2013; **3**: e003057.
- 19 Zwarenstein M, TrewEEK S, Gagnier JJ, Altman DG, Tunis S, Haynes B, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. *BMJ* 2008; **337**: a2390.
- 20 Greenhalgh T. Outside the box: Moving on. *Br J Gen Pract* 2013; **63**: 649.
- 21 Greenhalgh T. Outside the box: Why are Cochrane reviews so boring? *Br J Gen Pract* 2012; **62**: 371.